Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Rhea-AI Summary

Black Diamond Therapeutics (BDTX), a clinical-stage oncology company focused on developing MasterKey therapies for cancer patients, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Mark Velleca will engage in a fireside chat on June 4, 2025 from 4:20-4:50pm ET in New York. The company will also conduct one-on-one investor meetings during the event. A webcast of the presentation will be accessible through Black Diamond's website and remain archived for 90 days post-event.

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025 in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day.

Presentation details are as follows:

• 4:20-4:50pm ET on Wednesday, June 4
  

The Webcast will be available at the start of the presentation on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts

For Investors:
investors@bdtx.com

For Media:
media@bdtx.com 

FAQ

When is Black Diamond Therapeutics (BDTX) presenting at the Jefferies Healthcare Conference 2025?

Black Diamond Therapeutics will present at the Jefferies Healthcare Conference on June 4, 2025, from 4:20-4:50pm ET in New York.

Who will represent BDTX at the Jefferies Global Healthcare Conference 2025?

Mark Velleca, M.D., Ph.D., the Chief Executive Officer of Black Diamond Therapeutics, will represent the company in a fireside chat.

How can investors access Black Diamond Therapeutics' Jefferies conference presentation?

The presentation webcast will be available on Black Diamond Therapeutics' website (www.blackdiamondtherapeutics.com) in the investor relations section and will be archived for 90 days after the event.

What type of company is Black Diamond Therapeutics (BDTX)?

Black Diamond Therapeutics is a clinical-stage oncology company that develops MasterKey therapies targeting families of oncogenic mutations in cancer patients.